Cowen & Co. Sticks to Its Buy Rating for Mersana Therapeutics Inc

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Mersana Therapeutics Inc (NASDAQ: MRSN) yesterday. The company’s shares closed yesterday at $16.51.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 17.1% and a 52.2% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Jounce Therapeutics Inc.

Currently, the analyst consensus on Mersana Therapeutics Inc is Strong Buy and the average price target is $27.33, representing a 65.5% upside.

In a report issued on May 8, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $30 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.01 and a one-year low of $12.45. Currently, Mersana Therapeutics Inc has an average volume of 124.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.